Sex Differences in Stroke

L. Christine Turtzo    Louise D. McCullough
Department of Neurology and Neuroscience, University of Connecticut Health Center, Farmington, Conn., USA

Sex Differences in Stroke Epidemiology

The incidence of stroke is higher in men until advanced age, with a higher incidence of stroke in women after age 85 years [2]. Each year more women than men die from stroke, with women accounting for 61% of deaths in the US in 2004 [2]. This difference may result from a combination of the longer life expectancy of women and the increasing incidence of stroke with age. There is a trend for increased stroke severity [3] and greater mortality in women versus men after stroke [2]. Of those with a first stroke, the percentage of those with a recurrent stroke within 5 years is higher in women than in men (22% of women vs. 13% of men 40–69 years old; 28% of women vs. 23% of men ≥70 years old) [2].

Female sex is associated with poorer functional outcome after acute ischemic stroke (only 22.7% of women are fully recovered by 6 months vs. 26.7% of men) [3].
Women are more likely to be severely disabled at the time of discharge compared to men (36.1 vs. 24.2%) [4]. Women are less likely than men to be discharged home after a stroke admission (40.9 vs. 50.6%) [5], and are more likely to be discharged to long-term care upon hospital discharge (10 vs. 5%) [6].

Some of these disparities in functional outcomes may be secondary to the older age of women at the time of first stroke (74.5 vs. 69.2 years) and the fact that women are more likely to have been institutionalized prior to their first stroke (7.9 vs. 3.7%) [7]. After controlling for age, several studies found increased long-term mortality in men versus women after stroke [8–10] in contrast to other studies [2, 11].

Since women have strokes at older ages than men, age is a confounding factor in the analysis of these and other apparent sex differences in stroke and may diminish the effect of some of these discrepancies. However, some of these effects persist even after consideration of confounders. After controlling for confounding variables such as age, comorbidity, prestroke functional status, and stroke severity, women are less likely than men to receive a Barthel Index of 95 or greater (OR 0.75; 95% CI 0.61–0.94) [12]. Even controlling for prestroke living conditions, more women than men still require institutional care at 3 months after stroke [13], and are less likely to achieve independence in activities of daily living [14].

Women are also more likely than men to report and experience depression after stroke [15–17], possibly making recovery from stroke more difficult [18, 19]. Other important factors may include social support, sociocultural sex roles, and resources. Because women live longer than men, many more women are ‘surviving spouses’ and living alone; these individuals may have worse functional outcomes or simply be unable to care for themselves at home, although this has not yet been assessed in any prospective studies.

**Sex Differences in Acute Stroke Care**

Differences exist in the utilization of medical resources by men and women. A sex disparity in the access of patients to acute stroke care exists, with women 10% less likely to be admitted to the hospital within the first 3 h of stroke onset than men [20]. While several studies have found no statistical difference in intravenous (IV) tPA utilization between men and women during the treatment window [21, 22], a female stroke patient’s overall chances of receiving thrombolysis are 13% less than a male’s [20]. A Canadian study found that this discrepancy persisted despite controlling for confounding variables including age, comorbidity, prestroke functional status, and stroke severity, with an OR of 0.51 for women to receive tPA relative to men (95% CI 0.35–0.71) [12].

The disparity in a woman’s chances to receive thrombolysis may be related to a delay in presentation beyond the 3-hour treatment window. As more elderly women live alone at the time of their first strokes [7, 13], and have unknown time of onset of symptoms, they may have difficulty reaching medical attention within the accepted 3-hour window for IV tPA administration. However, one study found that the decreased likelihood of IV tPA treatment in women (OR 0.56; 95% CI 0.37–0.86) persisted even when analysis was restricted to patients arriving within 2 h of symptom onset, and was most likely in patients younger than 75 years [23]. The possibility of potential ‘undertreatment’ of women needs to be carefully assessed as recent studies [24] suggest a possibility of improved recanalization rates in women compared to men after thrombolysis.

Several studies have investigated whether sex disparities exist in the response of patients to thrombolytic therapy. Analysis of pooled data from several American and European IV tPA trials found that women who received IV tPA between 0 and 6 h of symptom onset were more likely to have a modified Rankin score ≤1 at 90 days poststroke than women who received placebo (40.5 vs. 30.3%) [25]. Men, in contrast, did not have a statistically significant benefit from IV tPA treatment in this pooled analysis [25]. Another study found that women were more likely than men to demonstrate substantial neurological improvement in the first 24 h after IV tPA treatment (OR 2.4; 95% CI 1.12–5.13) [26].

Results from the GAIN Americas trial found a different trend in patients treated within the approved 3-hour window. In this study, men were more likely than women to achieve better functional outcomes at 3 months by both the Barthel index and by a modified Rankin score [27]. A crucial limitation of the GAIN Americas study, however, is that rapid responders to IV tPA were excluded. Since women are more likely to show major neurological improvement in the first 24 h after IV tPA treatment [26], the exclusion of rapid responders from the GAIN Americas study may have negated the sex effect seen in the pooled analysis [25].

Similarly to IV tPA, women treated with intra-arterial (IA) prourokinase after middle cerebral artery occlusions showed a greater response to treatment than men (20 vs. 10%) [28]. However, it is important to note that no sex
disparity existed with respect to the IA thrombolytic treatment itself. Instead, a sex difference was noted in the untreated ‘placebo’ group, with only 17% of untreated women achieving a modified Rankin score of 0–2 at 90 days versus 31% of untreated men [28], suggesting that functional outcomes are worse in untreated women.

The Canadian Alteplase for Stroke Effectiveness Study (CASES) examined outcomes in 615 men and 505 women who received IV tPA [29]. In contrast to the GAIN Americas trial, all patients, including early responders to tPA, were included in CASES [29]. No difference in 90-day functional outcome or mortality was seen between men and women treated with IV tPA in CASES [29]. CASES itself only enrolled stroke patients who had received tPA; therefore, data on functional outcomes in untreated patients are only available from historical controls. After stroke women have worse functional outcomes than men [3, 6, 25]. The absence of a gender difference in functional outcome at 90 days after IV tPA treatment in CASES suggests that tPA treatment may benefit women more than men, since untreated women would be more likely to do worse after stroke than untreated men.

Whether treatment with tPA leads to different recanalization rates between men and women is still a topic of debate, with one prospective analysis showing higher rates in women (94 vs. 59%) treated with IV tPA [24], while a smaller study of IA tPA showed no differences [28]. Larger studies need to be designed to specifically determine if the risks and benefits of reperfusion therapies differ based on sex. The results of CASES suggest that these studies should be designed to not just look at treatment groups, but also at untreated patients, given that functional outcomes between the genders vary at baseline.

**Stroke Symptom Presentation**

Another possible explanation for the sex disparities seen in acute stroke care may be difficulty diagnosing a stroke at the prehospital level or in the emergency department. A prospective observational study of patients with validated stroke in community emergency departments found that women were more likely than men to present with nontraditional stroke symptoms such as pain, a change in level of consciousness, nonspecific, or unclassifiable neurological symptoms (28 vs. 19%) [30]. Men were more likely than women to report traditional stroke symptoms such as hemiparesis or imbalance [30]. This sex difference in the rate of atypical presentation of stroke parallels that seen in acute myocardial infarction (MI) [31]. As women may present with nontraditional stroke symptoms, it may be more difficult for both patients and medical providers to recognize the clinical situation in a timely fashion. Additional clinical research is needed to identify barriers to care in women and improve access for all patients with acute stroke.

**Sex Differences in Stroke Evaluation**

Recent research suggests that not only do women have atypical stroke presentations that could potentially delay treatment, but they may undergo different diagnostic procedures once a stroke is identified. One American study found that 71% of males with ischemic stroke versus 62% of females with ischemia stroke underwent evaluation of their carotid arteries, and 57% of men versus 48% of women had echocardiography, although MRI utilization rates were similar [32]. This is mirrored in European data as well. Women with stroke were less likely than men to have carotid duplex imaging (32.8 vs. 44.0%), echocardiography (22.8 vs. 30.5%), or angiography (5.5 vs. 9.5%) [7].

It has been known for some time that women tend to have more cardioembolic strokes than men, likely due to higher rates of atrial fibrillation in women [4, 13]. A Spanish study recently found that women were less likely to experience lacunar and atherothrombotic strokes [4]. Rates of hemorrhagic stroke were not statistically different between women and men [4]. Whether or not the sex differences observed in diagnostic testing correlate with differences in stroke presentation and etiology is unknown. This merits further study to ensure that both men and women receive appropriate care after a TIA or stroke occurs.

**Sex Differences in Stroke Prevention: Atrial Fibrillation**

Atrial fibrillation is an independent risk factor for ischemic stroke, with an age-adjusted risk ratio of 4.8 [33]. For patients with both coronary artery disease and atrial fibrillation, the risk of stroke doubles in men, but increases almost 5-fold in women [34]. When off anticoagulation therapy, women with atrial fibrillation have higher annual incidence rates of both ischemic stroke and peripheral thromboembolism than men (3.5 vs. 1.8%; RR 1.6) [35]. Both male and female patients with atrial
fibrillation on anticoagulation therapy have reduced rates of thromboembolism (RR 0.6 and 0.4, respectively) [35]. Anticoagulation should be strongly considered for stroke prevention in all patients with atrial fibrillation; however, women may benefit even more than men from treatment. Reducing the time spent off anticoagulation may also be especially important for women.

**Sex Differences in Primary Stroke Prevention: Aspirin**

Previous clinical trials have largely ignored the potential for sex-specific responses to treatments or the possibility that endogenous or exogenous sex steroids may interact with treatments used for stroke treatment or prevention. However, there is now evidence of important sex differences in the response to pharmacological agents commonly prescribed for vascular disease prevention. Aspirin has been well-studied in the primary and secondary prevention of vascular disease.

The Women's Health Study evaluated 39,876 healthy women in order to determine the efficacy of aspirin for the primary prevention of cardiovascular events and stroke [36]. Women received either 100 mg of aspirin every other day or placebo and were followed for 10 years. Aspirin lowered the risk of ischemic stroke by 24%, but did not alter the risk of MI or death [36]. This finding is in direct contrast to those of the Physicians Health Study which examined a similar, but male-only cohort (fig. 1). In men, aspirin had no effect on stroke risk but substantially reduced the risk of MI [37]. A recent meta-analysis of aspirin efficacy for the primary prevention of cardiovascular events showed similar results [38]. Women treated with aspirin had a 17% risk reduction for stroke, but no reduction in MI rates or cardiovascular mortality [38]. In matched males, aspirin therapy reduced MI rates by 32% yet had no effect on stroke risk [38]. Whether similar clinical differences exist with respect to other antiplatelet agents or other pharmacological agents is currently unknown. The utilization of ‘sex-specific’ data analysis provides clear evidence that sex plays a critical role in the phenotypic expression of vascular disease and its treatment.

**Sex Differences in Secondary Prevention of Stroke: Medical Management**

A retrospective cross-sectional study in Scotland involving patients with stroke found a disparity in the use of accepted secondary prevention strategies between men and women [39]. While the overall age-standardized prevalence of stroke was higher in women than in men (2.8 vs. 2.6%), women were less likely than men to be prescribed an angiotensin-converting enzyme inhibitor, a statin, or an antiplatelet in cases of ischemic stroke [39]. Of ischemic stroke patients with atrial fibrillation, women were not as likely to be prescribed warfarin as men but were more likely to be given an antiplatelet [39]. Another study found that men with over 85 years were more likely to get antiplatelet therapy than women of similar age after stroke [5]. In contrast, a prospective cohort study from Germany found few sex differences in medical management after stroke or TIA, with the exception that women were more likely to receive hypoglycemic agents in the acute management phase [40].

These sex differences in stroke management could have a profound clinical impact. Since women are more likely than men to have cardioembolic strokes, women with atrial fibrillation warrant treatment with warfarin when not contraindicated. Likewise, since women benefit more from aspirin for stroke prevention than men, aspirin should be considered for primary prevention. Given that women are more likely to have hypertension than men, blood pressure medications should be prescribed in women for stroke prevention according to JNC-7 guidelines [41]. This also holds true for women who have experienced a stroke, as vigorous risk factor control is required to prevent a future, potentially fatal, event.

**Sex Differences in Carotid Stenosis Management**

Women with ischemic stroke are less likely to have carotid surgery than men (0.3 vs. 1.5%) [7]. The risk-benefit ratio for surgical versus medical treatment of carotid stenosis differs in men and women and is also a topic of debate. While patients with symptomatic atherosclerotic carotid stenosis of 70–99% benefit from carotid endarterectomy [42, 43], female sex is classified as a surgical risk in these patients [44], with a higher risk of operative stroke and death in women than in men (systematic review of 25 studies: OR 1.31; 95% CI 1.17–1.47) [45]. The long-term risk of stroke or death after surgery in patients with high-grade symptomatic carotid stenosis is the same between the sexes (HR 1.05) [46]. In patients with moderate symptomatic (50–69%) [47, 48] and asymptomatic [49] carotid stenosis, men appear to benefit more from carotid endarterectomy surgery than women.
Men with asymptomatic high-grade stenosis (>70%) are at higher risk for vascular events than women when treated with medical management alone (HR 2.48), regardless of age or other vascular risk factors [50]. Interestingly, while there is no effect of treatment delay on response to carotid endarterectomy in men, one exists in women [51]. Women with symptomatic carotid artery stenosis benefit from carotid endarterectomy if the surgery is performed within 2 weeks of their most recent event, but the surgical benefit rapidly disappears if surgery is delayed beyond that point [51]. Whether these trends will be confirmed in larger studies, or if they are also present in patients that undergo carotid stenting, the necessity of dichotomizing trials and outcomes based on sex is becoming increasingly evident.

**Clinical Considerations**

Based upon AHA guidelines and the data described above, any patient, regardless of sex, who presents within 3 h of ischemic stroke and meets eligibility criteria should be offered treatment with IV thrombolytic therapy. Aspirin should be considered for the primary prevention of stroke in women. Anticoagulation should be strongly considered for primary stroke prevention in any patient with atrial fibrillation, but especially in women, given their higher rates of cardioembolic strokes. Treatment of hypertension should be pursued in all patients for stroke prevention.

The reasons for the clinical differences observed in presentation, treatment, and outcome of stroke in men and women are likely multifactorial. Some may result from differences in socioeconomic factors such as ad-
advanced age, comorbid illnesses or decreased social support. Others may be secondary to failures to recognize stroke symptoms in women as easily as men, delaying treatment. Yet others result from differences in biology between men and women. Clearly new data on the effects of aspirin and response to tPA suggest that there are unknown biological differences between women and men. The next several sections will discuss stroke in the context of different hormonal environments which are unique to women.

### Hormone Replacement Therapy and Stroke

Women are relatively ‘protected’ from stroke prior to the menopause, an effect that has been ascribed to gonadal hormones. Over the past 30 years, the majority of cohort, retrospective, or prospective observational studies have demonstrated significant reductions in cardiovascular disease in postmenopausal women receiving estrogen or combined estrogen-progesterin therapy (HRT) [52, 53]. Observational reports for stroke are not as clearly positive as those for cardiovascular disease [52]. Over the past decade, several major randomized clinical trials have been completed that address the role of HRT in both primary and secondary prevention of stroke. All trials to date have shown either no effect or an increased risk of stroke with treatment.

#### HRT and the Secondary Prevention of Stroke

Several randomized clinical trials investigated whether there is a role for HRT in the secondary prevention of stroke in postmenopausal women (table 1). Postmenopausal women with heart disease on HRT in the Heart and Estrogen/Progestin Replacement Study (HERS) trial showed no benefit with respect to cardiovascular disease endpoints. Treated women were at higher risk of thromboembolic events relative to placebo controls (relative HR 2.89) [54]. In the Women’s Estrogen for Stroke Trial (WEST), postmenopausal women with a recent stroke or transient ischemic attack (within 90 days of randomization) treated with estradiol-17β experienced a higher risk of fatal stroke (RR 2.9) compared to placebo-treated women, with the majority of the risk attributed to an increase in fatal ischemic stroke (RR 4.4) [55]. The Stroke Prevention in Atrial Fibrillation (SPAF) III trial also showed an increased risk of ischemic stroke in postmenopausal women on estrogen replacement therapy (RR 3.2) [56]. Currently there is no role for the use of HRT for the secondary prevention of either heart disease or stroke.

#### HRT and the Primary Prevention of Stroke

The Women’s Health Initiative (WHI) was a large multicenter double-blinded, randomized placebo-controlled trial that investigated the effect of estrogen plus...
progestin or estrogen alone for the primary prevention of stroke [57] (table 1). Both arms of this study were terminated early due to concerns of increased vascular risk in treated women. These results suggest that neither combined estrogen plus progestin nor estrogen treatment should be used for the primary prevention of stroke; however, the timing of hormone supplementation may be critical in interpreting these results.

Timing and Age of Cohort/Estrogen Exposure

Both the WHI Estrogen-Plus-Progestin Trial and the WHI Estrogen-Alone Trial have been the subject of great debate in the literature [58]. One major issue is the age of the women given estrogen. In laboratory models estrogen is potently neuroprotective when given immediately after menopause [59–63]. However, animals are usually young and are made ‘surgically’ menopausal via ovariectomy prior to an induced stroke. In clinical stroke, patients are often elderly, with all the associated comorbidities associated with aging. Women enrolled in the WHI were much older than women in the previous observational cohorts, and were often over a decade past menopause. The effect of returning estrogen to a possibly diseased vasculature after years of limited exposure may be detrimental.

Clinical trials are now underway to address whether or not the timing of HRT after menopause explains the discrepancy between our laboratory and clinical studies. The Kronos Early Estrogen Prevention Study (KEEPS) is a randomized, blinded, placebo-controlled multicenter clinical trial designed to address some of the problems noted with estrogen replacement in the WHI, WEST, and HERS trials [64]. Healthy women aged 42–58 years who are recently menopausal, with no menses for a minimum of 6 and a maximum of 36 months prior to randomization are being enrolled in this 5-year trial [64]. KEEPS will examine the effect of oral (0.45 mg daily conjugated equine) or transdermal (50 μg daily) estrogen with progesterone to placebo on carotid intimal medial thickness and coronary calcium deposition. It is important to note that these are surrogate markers rather than stroke incidence, as stroke is a relatively low incident event compared to coronary disease [64]. A subsequent analysis of the WHI data that segregated results based on age since menopause also showed no benefit of HRT on stroke [65]. Similar results have been found in the WHIMS cognitive dementia prevention trials [66–70]. The vast majority of previous studies used oral estrogen supplementation. This may increase the risk of thrombosis, as it leads to hypercoagulability, an effect that can be avoided with transdermal dosing.

Why are we having such difficulty translating the potentially beneficial effects of estrogen to humans? Many other neuroprotective agents have also failed to translate from bench to bedside [71], but the vast majority of these agents have not been as well studied as estrogen, which consistently shows beneficial effects in ‘clinically relevant’ animal models that are engineered to express common comorbid diseases such as diabetes and hypertension as well as in aging models [72, 73].

Short-Term Effects of Estrogen in Stroke

One possible reason for the failure of translation of estrogen’s neuroprotective effects to humans may be secondary to the timing and duration of treatment. While clinical trials to date have focused on chronic estrogen treatment, experimental evidence indicates that acute, short-term estrogen treatment during reperfusion limits damage from induced cerebral ischemia in animal models [63, 74]. Estrogen may enhance repair and plasticity after a stroke has occurred, as it has been shown to increase neurogenesis [75]. These data suggest that there may be a role for estrogen in the acute therapy of stroke during reperfusion, although no clinical data exist on this topic.

Stroke in Pregnancy and the Postpartum Period

While the risk of stroke in premenopausal women is in general much lower than postmenopausal women and older men, there is a higher incidence of stroke in women aged 15–35 compared to men [76], a period that coincides with the prime child-bearing years. For a more detailed clinical review of stroke in pregnancy, we direct the readers to an excellent recent review [77]. While several retrospective and prospective clinical trials have demonstrated an increased risk of stroke in pregnancy, data on stroke in pregnancy or the postpartum period in animal models are virtually nonexistent.

Only one animal study that examined the effects of pregnancy has been published which demonstrated increased neuronal damage in gestational day 17 pregnant rats after a global hypoxic insult [78]. It is important to note that the greatest risk for pregnancy-related strokes occurs in the peripartum and immediate postpartum period [79–82] rather than at end of pregnancy, and the ma-
For example, the protective effect of estrogen in ovariectomy monkeys fed atherogenic diets was only observed if there was no delay between ovariectomy and the start of hormone replacement [92]. A recent experimental study in mice confirmed that the timing of estrogen replacement is critical to stroke outcome [75]. As expected, estrogen treatment given immediately at the time of ovariectomy reduced stroke damage and attenuated central and peripheral production of proinflammatory cytokines. In contrast, estrogen treatment had no effect when it was administered 10 weeks postovariectomy and the animals were subsequently subjected to stroke. The interaction between age, estrogen, vasculature, inflammation, and duration of exposure is not yet clear in animal models, and certainly less so in women.

**Sex Steroid Hormone Receptors and Cerebrovascular Disease**

Estrogen interacts with two different nuclear receptors, ER-α and ER-β, both of which act in concert with other transcription factors to regulate gene expression [85, 89]. ER-α is present in pial arteries and intracerebral blood vessels [93–95], localizing to both vascular smooth muscle cells and endothelial cells [93–95], and its protein expression is upregulated in cerebral blood vessels after in vivo treatment with estrogen [96]. Little is currently known about the role of ER-β in the cerebral vasculature, although it has been detected in immunoblots of cerebral artery lysates [89, 93].

ER-α is thought to mediate most of the protective effects of estrogen on the vasculature. A 31-year-old man with a nonfunctional ER-α protein secondary to a premature stop codon in ESR1 had premature coronary atherosclerosis [97]. Certain polymorphisms of ESR1 have been associated with cerebrovascular [98–100] and cardiovascular disease [101–104] in men. Interestingly a different ESR1 polymorphism confers an increased risk of MI in women [105] (table 2), suggesting some interaction of ESR polymorphisms with sex or hormone exposure. However, several cross-sectional, case-control and cohort studies have not found any association between this polymorphism and risk of cardiovascular or cerebrovascular disease [100, 104, 106, 107]. Variation in the ER-β gene (ESR2) has also been associated with an increased risk of cardiovascular disease in women [108].

An interaction between sex, genetics, and vascular disease risk is suggested by the association of different ESR1 genotypes with cardiovascular disease in men in

---

For the full text, please refer to the source: Cerebrovasc Dis 2008;26:462–474
one study [103] but in women in another [105], and an association between different ESR2 genotypes and cardiovascular disease in women [108]. Given the genetic variability in humans, teasing out the underlying mechanisms will depend upon correlation with mouse models, in which the differences between genetic backgrounds can be more readily controlled.

### Sex versus Hormone Differences in Cell Death

Recent evidence suggests that not all ‘sex differences’ are mediated by hormones. Increasing attention has been directed at sex as an important modulator of ischemic cell death pathways. In work by Du and colleagues it was found that cortical neurons derived from male (XY) versus female (XX) embryos had strikingly different responses to ‘ischemic-like’ insults [109]. Male cells were more sensitive to oxidant damage via a nitric oxide pathway, where female cells were much more sensitive to inducers of apoptosis and caspase-mediated cell death. Similarly, female-derived organotypic hippocampal slices experienced less injury than male-derived cultures when exposure to N-methyl-D-aspartic acid or oxygen and glucose deprivation [110]. When the neuronal nitric oxide synthase (nNOS) inhibitor 7-nitroindazole was added to these organotypic cultures, cell death after oxygen and glucose deprivation was lessened in male cultures but not in female cultures [110]. These findings have been confirmed in neonatal (where hormones are less of a contributor to outcome) and adult animal models of injury [102, 103].

A well-described pathway leading to ischemia-induced neuronal cell death results from the overstimulation of nNOS [110]. Increased nNOS activity results in enhanced production of nitric oxide, peroxynitrite formation, and nitrosative DNA damage and activation of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase-1 (PARP-1) [110]. Genetic deletion of nNOS or PARP-1 is neuroprotective in male mice, but resulted in increased damage in female mice after middle cerebral artery occlusion [111]. Interestingly, both nNOS and PARP-1 knockout ovariectomized female mice showed no neuroprotective benefit of 17β-estradiol after middle cerebral artery occlusion, suggesting that interference with this pathway completely negates the beneficial effects of estrogen in vivo [111].

These data suggest that there are sexually dimorphic pathways leading to cell death after experimental ischemia. Whether these pathways are solely dependent upon sex steroid hormones or have any clinical relevance is presently under investigation. Data from a related mechanism of injury in neonatal animals, hypoxic-ischemic (HI) injury, may elucidate some of these answers.

### Sex Differences in Neonatal HI Injury

Cerebral palsy (CP), which is typically secondary to an acquired injury, is more common in males than females [112]. The incidence of CP is 30% higher in males than females [113]. Even after preterm birth, female infants have better outcomes than males [114–117]; the reasons for this sex disparity are not understood. One type of injury that commonly leads to CP is a HI insult. HI has been studied extensively preclinically. In adult mice exposed to unilateral HI, adult females exhibited less damage than males [118], presumably due to the neuroprotective effect of ovarian hormones. However, even in neonatal rodents, the response to HI injury in neonatal animals varied in a sex-specific manner, and differential cell death pathways

---

**Table 2. Estrogen receptor polymorphisms**

<table>
<thead>
<tr>
<th>Study</th>
<th>Estrogen receptor</th>
<th>Polymorphism/mutation</th>
<th>Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case report [97]</td>
<td>ER-α</td>
<td>Nonfunctional truncation</td>
<td>Premature coronary artery disease in male</td>
</tr>
<tr>
<td>Case-control study [98]</td>
<td>ER-α</td>
<td>PvuII polymorphism</td>
<td>Increased risk of stroke</td>
</tr>
<tr>
<td>Prospective cohort study [103]</td>
<td>ER-α</td>
<td>CC genotype of ESR1 c.454-397C</td>
<td>Increased risk of MI in men</td>
</tr>
<tr>
<td>Prospective cohort study [105]</td>
<td>ER-α</td>
<td>TT genotype of ESR1 c.454-397C</td>
<td>Increased risk of MI in females</td>
</tr>
<tr>
<td>Prospective study [99]</td>
<td>ER-α</td>
<td>CC genotype of ESR1 c.454-397C</td>
<td>Increased risk of stroke in men</td>
</tr>
<tr>
<td>Case-control/cohort study [104]</td>
<td>ER-α</td>
<td>ESR1 IVS1-397T/C polymorphism</td>
<td>No effect on risk of cardiovascular disease</td>
</tr>
<tr>
<td>Case-control study [100]</td>
<td>ER-α</td>
<td>ESR1 c.454-397T&gt;C</td>
<td>No effect on stroke risk</td>
</tr>
<tr>
<td>Case-control study [108]</td>
<td>ER-β</td>
<td>ESR2 rs1271572 variant</td>
<td>Increased risk of cardiovascular disease in women</td>
</tr>
</tbody>
</table>
were activated in the male versus the female brain [119]. These sex differences suggest that hormone exposure cannot fully explain the different responses to ischemia. Moderate hypothermia after neonatal HI was more protective in female than male rat pups [120]. Disruption of the PARP-1 gene in mice protected males from perinatal HI, but not females [121], similar to the results seen in adult mice [111]. Immature (postnatal day 9) male mice displayed greater translocation of apoptosis-inducing factor, a downstream effect of PARP activation, in brain in response to HI, while immature female mice had more activation of caspase-3 [118]. Agents used to treat neonatal HI experimentally also varied in their efficacy depending on the gender of the animal [122]. The caspase inhibitor Q-VD-OPh protected postnatal day 7 female rats from focal ischemia, while males showed no benefit, emphasizing the importance of caspase activation in the female brain [123].

These data suggest that different molecular mechanisms of brain injury are operational between the sexes that are unrelated to circulating sex hormone levels, as endogenous circulating estradiol is quite low in neonates. The organizational effects of steroids cannot be ignored and may still play some role in the response to ischemia but possible differences in basic ischemic cell death pathways are intriguing and merit further investigation. Clearly agents that are designed to interfere with NO or PARP signaling may have little effect or could paradoxically increase damage in females. Similarly, interfering with caspase-mediated cell death in males may have little benefit. These are critical issues as we continue in our attempt to translate neuroprotection from the bench to the bedside.

Conclusions/Further Directions

Sex differences in stroke are present from the clinical through the molecular level. The reasons for these observed differences in clinical stroke between men and women are multifactorial, and merit further investigation. Once the reasons for these differences are better understood, intervention might be possible to help provide the best care for all patients. Some of the differences in clinical stroke result, however, from biological differences between males and females with respect to stroke. We are only just beginning to understand these sex differences at a molecular level and to elucidate the role of sex steroids in the outcome from ischemic injury.

Acknowledgements

We would like to thank Dr. Isaac Silverman for his helpful comments in reviewing an earlier draft of this manuscript. This work was supported by the NIH (5R01NS050505-02 and 5R01NS055215-02 to L.D.M.).

References


Sex Differences in Stroke

Cerebrovasc Dis 2008;26:462–474

471
Sex Differences in Stroke

Cerebrovasc Dis 2008;26:462–474

473

Sex Differences in Stroke


